. The second principle is early excision and closure of the burn wound. Timely removal of burned tissue has been identified as an important determinant of survival after a major burn injury (7) (8) (9) and is immensely important in removing the very force that may be contributing to the lung injury. Hence, unlike many patients in the medical-surgical intensive care unit, patients with significant thermal injury typically require a series of major, staged operations under general anesthesia. In a patient with ARDS and severe oxygenation failure, this poses a formidable challenge, and surgical intervention should not be delayed or deferred in the scenario in which a patient is failing conventional mechanical ventilation (CMV). In this situation, a ventilatory strategy that effectively reverses oxygenation failure and that can be continued in the operating room would be distinctly advantageous.
In response to these unique requirements, we have utilized high-frequency oscillatory ventilation (HFOV) in our adult regional burn center since 1999. Initially, HFOV was employed as a rescue ventilation strategy for patients with extreme oxygenation failure from ARDS, despite maximum CMV. The marked and rapid improvements in oxygenation that occurred with HFOV allowed us to surgically excise the burn wounds of patients who would otherwise have been too unstable to tolerate a major operation under general anesthesia while continuing on maximal CMV. With recognition of the potential lung-protective benefits of HFOV (10 -14) , we have progressively used HFOV more frequently and earlier in the course of caring for a burn patient with acute lung injury or ARDS. This section of the Supplement will review our experience with HFOV in burn patients, our specific approach to the initiation and termination of HFOV, the special considerations for use of HFOV in burn patients with smoke inhalation injury, and our approach to use of HFOV during surgery.
Clinical Experience with HighFrequency Ventilation in Burn Patients
Published experience describing the use of HFOV in burn patients is fairly limited. Early case reports (14) and small case series (15, 16) , including our own preliminary experience (17) , generally found that HFOV was highly effective as a "rescue therapy" when maximal or near maximal CMV had been unsuccessful in reversing extreme oxygenation failure associated with ARDS. To date, we have used HFOV in 36 severely burned patients (mean Ϯ SD age, 42 Ϯ 15 yrs; percentage of total body surface area burn, 42% Ϯ 17%, with 33% rate of smoke inhalation), and we have analyzed data on our experience with the first 25 cases (18) . In that study, 24 of 25 patients met AmericanEuropean Consensus criteria for ARDS (3) and had a mean Ϯ SD PaO 2 /FIO 2 ratio of 98 Ϯ 26 and a mean oxygenation index (OI ϭ mean airway pressure ϫ FIO 2 ϫ 100/PaO 2 ) of 27 Ϯ 10 just before starting HFOV. Conventional ventilation just before HFOV had consisted of pressurecontrolled ventilation using an FIO 2 of 0.8 Ϯ 0.2, positive end-expiratory pressure of 13.7 Ϯ 3.5 cm H 2 O, inspiratory-toexpiratory ratio of 1:1.6, and peak inspiratory pressure of 28 Ϯ 5 cm H 2 O, with six patients receiving 16 Ϯ 6 ppm of inhaled nitric oxide (iNO). There was a significant and sustained increase in the PaO 2 /FIO 2 ratio within 1 hr and a significant and sustained reduction in the OI within 48 hrs of starting HFOV (Fig. 1) . Among the six patients who had been receiving iNO, all were weaned off iNO within 24 hrs of starting HFOV. Aside from three episodes of severe hypercapnia (PaCO 2 range, 92-136 mm Hg), there were no other complications related to HFOV such as gross barotrauma, hemodynamic instability, or inspissation of mucous secretions. HFOV was maintained for 6.1 Ϯ 5.8 days (range, 2 hrs to 26 days). Seven patients (28%) died receiving HFOV after a duration of HFOV treatment of 5.9 Ϯ 5.8 days (range, 2 hrs to 15 days). In the patients who died, the PaO 2 /FIO 2 ratio and OI immediately before death were 170 Ϯ 116 and 22 Ϯ 11, respectively. Refractory oxygenation failure was judged to be contributory in only one case (PaO 2 /FIO 2 ratio, 74; OI, 39). The underlying cause of death in all cases was sepsis with multiple organ dysfunction. The 18 survivors were converted back to CMV after 6.1 Ϯ 5.9 days (range, 5 hrs to 26 days) at an FIO 2 of 0.4 Ϯ 0.1 and a mean airway pressure (mP O aw) of 24.4 Ϯ 4.0 cm H 2 O. At this time, their PaO 2 /FIO 2 ratio was 238 Ϯ 109 and their OI was 13 Ϯ 9, both of which were significantly better than present on CMV immediately before starting HFOV (p Ͻ .001, each).
To summarize, HFOV has produced pronounced and sustained improvement in oxygenation in several of our burn patients with severe oxygenation failure secondary to ARDS. A progressive decline in the OI was also observed, indicating that the improvements in oxygenation occurred at a progressively lower "airway pressure cost" (19) . Our findings in this group of burn patients are very similar to observations made in the first two adult studies of HFOV in critically ill medicalsurgical intensive care unit patients (19, 20) .
High-Frequency Percussive Ventilation/Volume-Diffusive Respirator
High-frequency percussive ventilation (HFPV) has been more widely used in thermally injured patients and has received considerably more attention in the burn literature than has HFOV. HFPV is administered using a volumetric-diffusive respirator that incorporates a sliding Venturi called the Phasitron (21) . The volumetric-diffusive respirator delivers sub-dead space breaths at frequencies between 0.6 and 15 Hz. The sliding Venturi stacks the rapid pulsatile breaths to a selected peak airway pressure that is then interrupted at regular intervals (usually every 2 secs) by a phase of passive exhalation that allows the waveform and airway pressure to return to baseline continuous positive airway pressure, which is usually set between 5 and 10 cm H 2 O (21). Thus, the high-frequency percussive waveform is superimposed on a sinusoidal cyclic waveform of increasing and decreasing airway pressures (the phasic rate). There are several fundamental differences between HFOV and HFPV. First, the mP O aw is relatively constant and sustained during HFOV, whereas it fluctuates and is not sustained during HFPV. Second, during HFOV, the mP O aw is directly set, which immediately influences alveolar recruitment and oxygenation. In HFPV, the mP O aw can only be indirectly altered. Third, exhalation during HFOV is active, whereas exhalation is passive dur- ing HFPV. Fourth, because the Phasitron is pneumatically driven, the frequency and pressure amplitude of the highfrequency sub-dead space breaths are "coupled" (e.g., an increase in frequency results in a decrease in pressure amplitude and vice versa); in contrast, during HFOV, the frequency and proximal oscillatory pressure swings (⌬P) are adjustable independently. Finally, the percussive nature of the pulsatile breath pattern in HFPV promotes mucokinesis and clearance of secretions, which is aided by the fact that the endotracheal tube (ETT) cuff is kept deflated during HFPV.
The reported use of HFPV among burn patients has largely been restricted to those with an associated smoke inhalation injury. Two small case series suggest that HFPV is highly effective as a salvage ventilation strategy for patients with severe oxygenation failure after burns and smoke inhalation (22, 23) . HFPV has also been applied as a prophylactic ventilation strategy in burn patients with inhalation injury. A retrospective study by Cioffi et al. (24) , in which 54 patients were placed on HFPV within 1 hr of admission to the burn unit, found a significant reduction in the rate of pneumonia and the mortality rate, compared with predicted values from a historical cohort. More recently, a prospective study involving 35 adults with burns and smoke inhalation randomized patients to conventional volume-controlled ventilation or to HFPV (25) . The PaO 2 /FIO 2 ratios in the HFPV group were significantly higher than in the conventional group, but there were no differences between groups in peak airway pressures, rate of pneumonia, or mortality. To our knowledge, there have been no prospective, randomized clinical trials comparing HFPV with HFOV.
Specific Clinical Issues in Using HFOV in Burn Patients
Patient Selection. In a burn patient with ARDS, we generally consider using HFOV when there is moderate to severe oxygenation failure (usually with a PaO 2 / FIO 2 ratio of Ͻ150), despite relatively aggressive or escalating conventional mechanical ventilatory support (typically characterized by either an FIO 2 of Ͼ0.6 with positive end-expiratory pressure of Ն12.5 cm H 2 O or the need for inverse ratio ventilation or use of iNO to support oxygenation). The OI is also an important consideration. An OI of Ͼ30 is generally accepted to represent failure of CMV (19), but we have generally instituted HFOV when the OI is Ն25. The presence or absence of an associated smoke inhalation injury does not affect our decision to use HFOV. However, as will be discussed, we have found HFOV to be less effective in burn patients with smoke inhalation. Finally, the need to take a patient to surgery for burn wound excision also influences our decision to start HFOV. If burn excision is required and the patient is at or approaching the gas exchange and ventilatory variables described above, we are more inclined to switch over to HFOV as soon as possible before surgery. Our rationale for this approach is that in our hands, HFOV typically produces marked improvements in oxygenation over a relatively short period and thus provides a greater margin of safety and flexibility with respect to intraoperative ventilatory management than if the patient had been brought to the operating room remaining on CMV with poor oxygenation and high airway pressures.
Timing. Over the past 5 yrs, we have progressively initiated HFOV earlier in the patient's course. In 1999, we started HFOV after a mean of 7.3 days postburn in patients with a mean OI of 30, whereas in 2003, HFOV was started after a mean of only 2.5 days postburn in patients with a mean OI of 30. The effect of timing of initiation of HFOV on the course of ARDS remains unknown, but recent adult HFOV trials suggest that earlier institution of HFOV may improve outcome (19, 20, 26) .
Sedation Strategy. Early in our experience, we paralyzed all patients using vecuronium infusions. However, because most of our mechanically ventilated burn patients are heavily sedated with continuous infusions of morphine and midazolam, we have found that neuromuscular blockade is not absolutely required during HFOV, as long as the patient is well sedated. If the patient is inadequately sedated and making any respiratory efforts, one will observe swinging fluctuations in the set mP O aw. This suggests the need for increased sedation or paralysis. This contrasts sharply with mechanically ventilated patients in the medical-surgical intensive care unit, who are usually not as deeply sedated and who will likely require paralysis during HFOV.
Oxygenation Strategy. We set the initial FIO 2 at 1.0 and arbitrarily start with a mP O aw of 5 cm H 2 O above the mP O aw that was present while the patient was receiving CMV. This typically produces a tran- 18) . The percentage of inspiration time is set at 33% and the bias flow is set at 30 L/min to start. We now also routinely use one or more lung recruitment maneuvers (LRMs) just after initiation of HFOV. This consists of temporarily increasing the mP O aw to 40 cm H 2 O for a period of 20 -40 secs. There is substantial evidence from animal models that LRMs are essential in recruiting alveoli for optimal application of HFOV (27) . As long as the SpO 2 is Ͼ92%, the FIO 2 can then be titrated down from 1.0 to the pre-HFOV level. If the pre-HFOV FIO 2 Ventilation Strategy. During HFOV, alveolar ventilation is improved by increasing the power to increase the amplitude of oscillation or by reducing the frequency to increase the stroke volume. The latter maneuver is generally the most effective but is the least desirable because the larger tidal volumes at low frequen-cies may be sufficient to overstretch alveoli and cause injury (with an adultsized ETT and no cuff leak, using highpower settings and frequencies of 3-6 Hz, tidal volumes of 150 -260 mL are produced, which may be sufficient to produce stretch injury when the lung is inflated with a mP O aw of 30 cm H 2 O) (28, 29) . Most adult studies of HFOV (19, 20, 26, 30) , including our own (18) , have initiated HFOV at approximately 5 Hz and decreased this toward 3 Hz if increased CO 2 removal was necessary. There is no scientific basis for limiting frequencies to 5 Hz, and in neonates, HFOV frequencies of 10 -15 Hz are routinely used (23) . Optimal frequencies in adults are unknown but are probably higher than 3-5 Hz (23). Our current approach is to start with maximum power (9, 10) and a frequency around 6 -8 Hz. Chest and body vibration are then used to roughly guide the initial power and frequency settings. If vibration is excessive (e.g., chest vibrations are transmitted distal to the mid-thigh), then the power is decreased by increments of 1 unit every 5 mins until the target of midthigh "wiggle" is obtained. If chest wall vibration is too little (e.g., not transmitted to the mid-thigh level), then the frequency is reduced by 1 Hz every 5 mins until mid-thigh wiggle is obtained (usually this involves a reduction to around 5 Hz but should not go lower than 3 Hz). Subsequent adjustments are made based on arterial blood gasses. A permissive hypercapnia approach is used, allowing a PaCO 2 of Ͻ65 mm Hg and pH Ͼ 7.25. Hypercapnia with acidemia beyond these limits is first treated by increasing power to maximum if it is not already at 10 and, second, by reducing frequency by 1-Hz increments to a minimum of 3 Hz. If this is unsuccessful, we occasionally resort to an intentional endotracheal cuff leak, as described by Derdak (29) . An intentional cuff leak is produced by withdrawing air from the cuff until the mP O aw decreases by 5 cm H 2 O and then restoring the mP O aw to the preleak level with the mP O aw control dial. If this is unsuccessful in restoring the preleak mP O aw, the bias flow can be increased. We have used cuff leaks in eight cases to date. These were instituted for PaCO 2 levels ranging from 61 to 136 mm Hg, while administering frequencies between 2.8 and 5 Hz and power settings of 9 or 10. In two cases, the cuff leak alone was successful in correcting the PaCO 2 and pH to acceptable levels. In four cases, the cuff leak produced modest but insufficient corrections in the PaCO 2 , and ultimately, further reductions in frequency were required. In one case, a switch to CMV was required to correct hypercapnia. In the final case, severe hypercapnia (PaCO 2 of 136 mm Hg and pH of 7.10) persisted, despite a frequency of 3 Hz, amplitude of 109 cm H 2 O, and an intentional cuff leak. It was recognized that the intentional cuff leak from the oral ETT was probably ineffective due to severe head and neck edema that was blocking passive CO 2 egress in this particular patient. A 6.0-mm nasal ETT was inserted into the supraglottic hypopharynx to act as a "vent" for the cuff leak, which resulted in a PaCO 2 of 85 and a pH of 7.3 within 4 hrs and further reduction in the PaCO 2 to 60 mm Hg by 6 hrs while continuing HFOV at the same frequency and power settings (31) . The improvement in alveolar ventilation persisted for 48 hrs until the patient expired from multiple organ failure. Notwithstanding the aforementioned cases, hypercapnia has not been a significant problem in the vast majority of our HFOV cases, in which the mean Ϯ SD PaCO 2 was 51 Ϯ 12 mm Hg on a frequency of 4.6 Ϯ 1.1 Hz over the first 72 hrs of HFOV (18) .
Smoke Inhalation Injury and HFOV. Approximately 30% of our burn patients who receive HFOV have an associated smoke inhalation injury. In our institution, smoke inhalation injury is diagnosed at admission by direct visualization of the tracheobronchial mucosa using fiberoptic bronchoscopy. The presence of infraglottic soot, mucosal hyperemia, edema, slough, or ulceration are all considered positive signs of smoke inhalation injury. Serial examinations by the same experienced observer prove to be the most reliable. Unfortunately, there is an indistinct relationship between the severity of findings at bronchoscopy and the eventual extent of lung dysfunction from smoke inhalation injury. The response to HFOV in our patients who have had a smoke inhalation injury has been less impressive than among patients with a burn alone. Significant improvement in the PaO 2 /FIO 2 ratio from that on CMV occurred only after 72 hrs of HFOV in smoke inhalation cases, whereas in pa- tients without inhalation injury, significant improvements were seen after only 12 hrs. Similarly, although smoke inhalation patients showed a trend toward a lower OI, this never became significantly better compared with that on CMV. In those patients who had a burn alone, the OI was significantly better than on CMV within 24 hrs (Fig. 2) . There are no human studies of HFOV in smoke inhalation, but a study in primates has compared the prophylactic use of HFOV against HFPV after an experimentally induced smoke inhalation injury (32) . In that study, subjects receiving HFOV (n ϭ 3) were less successfully oxygenated and seemed to have more histologic evidence of ventilator-induced pulmonary injury than subjects receiving HFPV (n ϭ 5). Although this study was somewhat limited in extent, the findings mirror our clinical observations. A possible explanation may be the unique pathologic changes in the small airways that occur with smoke inhalation injury. Obstruction of the small airways by edema and by sloughing, necrotic epithelial mucosa combined with bronchospasm may prevent adequate alveolar recruitment, whereas in other areas of the lung, this same pathology may contribute to segmental gas trapping and overdistention with the application of sustained and elevated mP O aw, thus promoting alveolar stretch injury. Because lung volume is allowed to periodically return to baseline during HFPV, gas trapping and segmental overdistention may be better avoided relative to HFOV. Also, the mucokinetic effects of HFPV may promote enhanced clearing of the airways, thus preventing atelectasis and improving alveolar recruitment. In summary, although we do not consider smoke inhalation injury to be a contraindication to HFOV, we do recognize that the response to HFOV will likely be slower and less robust than in cases without an inhalation injury. Furthermore, in selected instances, especially when bronchorrhea is a prominent feature, the mucokinetic effects of HFPV offer a distinct advantage over HFOV for the burn patient with a smoke inhalation injury.
Use of HFOV in the Operating Room
Early surgical excision and closure of the burn wound is an integral part of the management of a patient with a major burn injury. However, subjecting a patient with acute lung injury or ARDS and moderate to severe oxygenation failure to a major operation under general anesthesia poses a substantial challenge, particularly with respect to perioperative mechanical ventilation. We realized early in our experience that the ability of HFOV to reverse severe oxygenation failure in a relatively short period of time created an important window of opportunity for the excision and closure of the patients' burn wounds. However, this presented the challenge of whether HFOV could be used in the operating room as opposed to temporarily converting back to CMV for the surgical procedure. We believe that interruption of HFOV for these operations would not only have posed a risk of alveolar derecruitment with the interruption in mP O aw but would also have diminished the consistency of the lung-protective effects of HFOV. Therefore, in an effort to take advantage of the improvements in oxygenation that occurred with HFOV, and wishing to maintain a consistent lung-protection strategy, we have developed an approach for continuing HFOV during surgery in the operating room.
The main obstacle is that HFOV cannot be continued during transport to the operating room. The electrical power requirements of the oscillator preclude the use of a battery, and two independent gas sources must be maintained (pressurized room air and oxygen). Hence, the patient must be temporarily detached from the oscillator, which poses a risk of alveolar derecruitment when the applied mP O aw is interrupted. To compensate for this, we have developed the following protocol. In the burn center, the patient is preoxygenated with 100% oxygen. The anesthesiologist transiently clamps the ETT with a Kelly clamp just distal to the teeth (Fig.  3) . Next, the HFOV circuit is detached and is exchanged for a Laerdal bag, with the positive end-expiratory pressure valve set at 20 cm H 2 O, which is then reattached to the still clamped ETT. When the Laerdal bag is attached, the ETT is unclamped. We believe that these steps minimize alveolar derecruitment due to the loss of mP O aw when HFOV is interrupted. Next, the burn unit respiratory therapist transfers the oscillator to the operating room ahead of the patient while the anesthesiologist manually ventilates the patient with 100% oxygen using short rapid breaths while following behind. In the operating room, the same sequence of ETT clamping and unclamping is used to switch the patient from the Laerdal bag to the HFOV circuit. HFOV then resumes using the same mP O aw and an FIO 2 of 1.0. At this point, it is often necessary to perform one or more LRMs (mP O aw increased to 40 cm H 2 O for 20 -40 secs) if there has been any decrease in oxygen saturation by pulse oximetry. If oxygenation has remained stable, patient positioning and surgery then proceed as usual after induction of general anesthe- sia using a total intravenous anesthetic (typically infusions of fentanyl and propofol are added to the existing infusions of morphine and benzodiazepines). If prone positioning is needed, the aforementioned steps of clamping and unclamping the ETT are taken to disconnect the patient during the positioning. During the procedure, the FIO 2 and mP O aw are adjusted by the anesthesiologist to maintain an SpO 2 of Ն92%, the goal being to resume the preoperative FIO 2 level as soon as possible. Frequency and power are manipulated to maintain the PaCO 2 between 35 and 60 mm Hg and the pH at Ͼ7. 25 . At the conclusion of the procedure, the steps of clamping and unclamping the ETT during changeover between HFOV and the transport Laerdal bag ventilation, as described above, are repeated.
To date, we have used HFOV for 33 surgical procedures in 18 patients. The PaO 2 /FIO 2 ratio and OI of these patients, just before being converted from CMV to HFOV, were 88 Ϯ 17 and 28 Ϯ 13, respectively. These indices reflect severe oxygenation failure on near maximal CMV and highlight the precarious state of these patients who required major surgery under general anesthesia. However, with initiation of HFOV and after a mean of 84 Ϯ 93 hrs (range, 0 -264 hrs) of treatment, the preoperative PaO 2 /FIO 2 ratio and OI had improved significantly to 216 Ϯ 106 and 19 Ϯ 10, respectively. These are levels of oxygenation at which there is clearly considerably more flexibility and safety. These improvements in oxygenation illustrate the concept of using HFOV to create a window of opportunity to allow surgery to proceed. One could argue that at these levels, continuation of HFOV was unnecessary and that resumption of CMV for surgery would have been feasible. However, as described above, we believe this would have carried the risk of allowing renewed alveolar derecruitment, along with loss of the potential lung-protective benefits of HFOV. During the operative procedures, a mean Ϯ SD of 20% Ϯ 11% of total body surface area burn was excised and closed with autograft, allograft, or skin substitutes during a mean operating room duration of 302 Ϯ 107 mins. Prone positioning occurred in 10 of 33 of the procedures (30%), and iNO was continued intraoperatively for two patients at concentrations of 7 and 10 ppm, with one patient receiving iNO and HFOV while prone. The mean Ϯ SD postoperative PaO 2 /FIO 2 ratio and OI were 242 Ϯ 78 and 17 Ϯ 6, respectively, which did not differ significantly from preoperative values. The minimum FIO 2 achieved intraoperatively was 0.6 Ϯ 0.2. There have been no complications associated with intraoperative HFOV use.
Conclusion
HFOV has been particularly useful in the care of our burn patients with ARDS. Initially, HFOV was used as a rescue ventilation strategy for severe oxygenation failure. However, it has been used progressively earlier in the course of burn patients care and has facilitated transfer of patients to the operating room for surgical excision and closure of the burn wound. Our enthusiasm for HFOV in the smoke inhalation patient is somewhat guarded at this time, and larger, prospective, randomized clinical trials are needed to assess the usefulness of HFOV after smoke inhalation.
